The U.S. Patent and Trademark Office (PTO) has granted the Medicines Company a one-year extension for its patent (Patent No. 5,196,404), covering its antithrombotic bivalirudin (Angiomax).
In March, the Parsippany, N.J.-based company filed a complaint through the U.S. Court of the Eastern District of Virginia alleging the FDA and the Department of Health and Human Services of overturning the Hatch-Waxman patent application for Angiomax. Last week, the court urged the PTO to consider Angiomax for an extension.
The company said it expects the patent expiry date of August 13, 2011 to appear in the FDA’s Orange Book.